Israeli pharma company Protalix BioTherapeutics has appointed Moshe Manor as its new president and chief executive, effective from November 2. 29 September 2014
UK pharma giant GlaxoSmithKline this morning confirmed recent rumors, saying that Sir Philip Hampton will join the company’s board as non-executive director from January 1, 2015, and will become deputy chairman with effect from April 1, 2015. 25 September 2014
Swiss-based iron deficiency specialist Vifor Pharma has appointed Dario Eklund as head of international business operations, and Abdul Mullick as head of global marketing, at its headquarters in Zurich. 19 September 2014
Pharmaceutical companies have widely adopted strategies to outsource elements of their business operations, as part of an ongoing drive to deliver a more flexible model that unlocks cost efficiencies and alleviates some aspects of risk associated with drug development. Recruiting talent is one such element. However, pharma companies should be wary of saving on recruitment at the risk of missing out on the best candidates, particularly when it comes to senior staff. Director of Interims of RSA, Dafydd Wright explains. 19 September 2014
The board of partners of Germany’s Merck KGaA has promoted Stefan Oschmann to the position of deputy chief executive and Vice Chairman of the Executive Board. 18 September 2014
USA-based PTC Therapeutics is to expand its global presence by adding key executives to leadership positions in the global commercial team and establishing its international headquarters in Dublin, Ireland. 17 September 2014
Oliver Siegel has been appointed as chief operating officer at Austrian vaccine specialist AFFiRiS AG, where he will take responsibility for business development, finance and administration. 9 September 2014
Swedish drug developer Karolinska Development has appointed Bruno Lucidi as chief executive of the wholly-owned subsidiary KDev Oncology, and portfolio companies Aprea and Akinion Pharmaceuticals. 8 September 2014
Belgian cell therapy company TiGenix has appointed Marie Paule Richard as chief medical officer, and Mary Carmen Diez as its vice president of medical affairs and new product commercialization. 1 September 2014
French drug major Sanofi has replaced its North American chief Anne Whitaker with Jez Moulding, who will be head of the region’s pharma business following a senior management role in Japan and Asia Pacific. 28 August 2014
Coming from her position as president of Sanofi’s North American pharma division, Anne Whitaker has been named chief executive of Synta Pharmaceuticals. 12 August 2014
Astellas Pharma EMEA, the regional headquarters of Japanese drug major Astellas Pharma, has appointed Simon Dew as chief strategy officer. 7 August 2014
Quebec-based cardiovascular drug development specialist Milestone Pharmaceuticals has announced the appointment of Francis Plat as chief medical officer. He is a cardiologist with extensive experience in cardio drug development. 21 July 2014
US-based drug development and discovery company Aptuit has appointed Paul Overton as executive vice president, business development and marketing. He is now responsible for all of Aptuit’s sales and marketing activities. 16 July 2014
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024
Lykos Therapeutics has announced a reorganization to best support the company as it works to address the resubmission of its new drug application (NDA) for midomafetamine capsules for the treatment of post-traumatic stress disorder (PTSD) in adults. 16 August 2024
German infectious disease specialist AiCuris Anti-infective Cures has announced the appointment of Cynthia Wat as chief medical officer (CMO). 30 July 2024
Ophirex, a registered public benefit corporation developing an oral field treatment to address the global unmet medical needs of snakebite victims, has announced the appointment of Jeremy Gowler as chief executive. 15 July 2024
US drugmaker AbbVie has announced that Roopal Thakkar, who currently serves as senior vice president, chief medical officer, global therapeutics, has been appointed to the position of executive vice president, research and development, and chief scientific officer (CSO). 10 July 2024